Kalaris Therapeutics, Inc.
KLRS
$4.90
-$0.32-6.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 15.94% | -4.79% | -11.32% | 53.71% | 42.16% |
| Total Depreciation and Amortization | 233.33% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | -99.48% | -- |
| Total Other Non-Cash Items | -89.77% | -4.06% | 165.02% | 101.08% | -163.39% |
| Change in Net Operating Assets | 32,022.22% | 99.49% | -175.87% | 320.90% | -189.62% |
| Cash from Operations | 37.73% | 9.62% | -68.51% | 5.22% | -81.44% |
| Capital Expenditure | 90.71% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 143.45% | -- | -- | -- | -- |
| Cash from Investing | 143.17% | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -100.00% | -24.80% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | 4,260.43% | -- |
| Cash from Financing | -- | -- | -100.00% | 1,315.69% | 757,600.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 220.91% | -267.17% | -112.56% | 36,532.85% | 93.67% |